Forging global networks in the imperial era: Atiya Fyzee in Edwardian London

This chapter examines the global networks forged by South Asians in Edwardian Britain through the eyes of Atiya Fyzee, a Muslim woman from Bombay. This era is perhaps the least well-served in the available literature on Indian travellers, students and settlers in Britain despite its frequent depiction as the apogee of British imperialism before the First World War began the process of decline. (Continues...

To write of the conjugal act: intimacy and sexuality in Muslim women’s autobiographical writings in South Asia

To write of the conjugal act: intimacy and sexuality in Muslim women’s autobiographical writings in South Asi

The heart of a Gopi: Raihana Tyabji’s bhakti devotionalism as self-representation?

Raihana Tyabji is best known to history, not for her writing or even her singing, but as a devotee of Gandhi. Yet in 1924 this at least nominally Muslim woman composed a small book of bhakti devotionalism that has continued to garner popular interest right into the twenty-first century. She gave it the evocative title, The Heart of a Gopi, on the basis that what had been revealed to her was the very 'soul', the inner self, of the gopi and, through that, an understanding of Lord Krishna himself. Considered in this paper then is the question of how far this piece of bhakti devotionalism may be read as a kind of personal narrative, an evocation of the self. Does the referencing of an established narrative tradition give the author's feelings and experiences, especially as a Muslim woman devoted to Krishna at a time of increasing religious rigidity and growing communal strife, a kind of validity not achievable otherwise? And, if so, how do we separate out the author's 'self' from the literary conventions – in this case, the gopi tradition – that structure the story? In the tradition of Islamic life writing, can the gap between the miraculous and the mundane be breached in order to understand the mystical experience charted here as a kind of autobiography? Even from the rationalist's perspective, should not the life of the imagination still be considered part of the life

Contesting seclusion : The political emergence of Muslim women in Bhopal, 1901-1930.

This study examines the emergence of Indian Muslim women as politicians and social reformers in the early years of the twentieth century by focussing on the state of Bhopal, a small Muslim principality in Central India, which was ruled by a succession of female rulers throughout the nineteenth and early twentieth centuries. The last Begam of Bhopal, Nawab Sultan Jahan Begam (1858-1930, r. 1901-1926), emerges as the main figure in this history, though a substantial effort has also been made to examine the activities of other Bhopali women, whether poor, privileged or princely. Special significance has been attached to their changing attitudes to class, gender and communal identities, using the veil as a metaphor for women's expanding concerns. Their connections with wider movements of social reform have also been emphasized in an attempt to show that the emergence of women in Bhopal was representative of a broader development occurring amongst Muslim women, both within India and throughout the Islamic world. The importance of this study lies in its treatment of the 'daughters of reform,' the first generation of Muslim women who contributed to the reformist discourse, particularly at the regional level, as complex subjects in possession of a history. It is also significant in that it redresses the paucity of academic literature on the princely states of India, highlighting the differences between states and the changes that occurred over time, rather than simply dismissing the princes as frivolous reminders of a by-gone age. The main theme that arises is the importance for early Muslim female activists of balancing continuity and innovation. By operating within the framework of Islam, Bhopali women were able to build on traditional norms in order to introduce incremental change. As many of their achievements were unforseen, however, their story is as much one of paradox, as of progress

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

BACKGROUND: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. METHODS: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). FINDINGS: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29-146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0- 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25-1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39-1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65-1·60]; p=0·92). INTERPRETATION: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention. FUNDING: British Heart Foundation

Life/History/Archive: Identifying Autobiographical Writing by Muslim Women in South Asia

For historians, the debates surrounding autobiography have focused on the question of reliability: can it be considered an appropriate historical source only when verified by ‘real’ material from ‘real’ archives? Scholars from other disciplines have been more interested in defining autobiography as a genre by asking if it can be distinguished from other literary forms. Far from hypothetical, these questions about where to draw the line are pertinent to the historian in the field faced with the very real problem of identifying materials. The problem seems compounded when the historian’s subject is Muslim women in South Asia, a group often characterised as silent and secluded and thus presumed not to write autobiography at all. As part of the task of ‘defining the genre’, this paper considers the range of possibilities to be included under the labels of personal narratives, life histories or, ultimately, autobiographical writing – from autobiographical biographies and biographical autobiographies to travelogues, reformist literature, novels, devotionalism, letters, diaries, interviews and ghosted narratives. It raises questions about the nature of archives and the distinctiveness of women’s writing as these relate to nomenclature, structure, chronology, language, voice and regional specificity

A princess's pilgrimage: Nawab Sikandar Begum's a pilgrimage to Mecca [introduction]

In 1863, the Nawab Sikandar Begum, a Muslim woman and hereditary ruler of the princely state of Bhopal in colonial India, traveled to Mecca with a retinue of a thousand people. On returning, she wrote this witty, acerbic account of her journey. In it, we glimpse a process by which notions of the self could be redefined against a Muslim "other" in the colonial environment. Sikandar Begum emerges as a genuinely complex individual, crafting an image of herself as an effective administrator, a loyal subject, and a good Muslim. Siobhan Lambert-Hurley's critical introduction and afterword make this edition a comprehensive resource on travel writing by South Asian Muslim women, colonialism, and world history